Literature DB >> 16045485

The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.

Mahmoud M Iravani1, Clement C M Leung, Mona Sadeghian, Claire O Haddon, Sarah Rose, Peter Jenner.   

Abstract

Sustained reactive microgliosis may contribute to the progressive degeneration of nigral dopaminergic neurons in Parkinson's disease (PD), in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposed human and in non-human primates. However, the temporal relationship between glial cell activation and nigral cell death is relatively unexplored. Consequently, the effects of acute (24 h) and chronic (30 days) glial cell activation induced by unilateral supranigral lipopolysaccharide (LPS) administration were studied in rats. At 24 h, LPS administration caused a marked reduction in the number of tyrosine hydroxylase-immunoreactive (TH-ir) neurons in the substantia nigra (SN) but striatal TH-ir was unaffected. By 30 days, the loss of TH-positive neurons in the LPS-treated nigra was no greater than at 24 h although a heterogeneous loss of striatal TH-ir was present. The loss of nigrostriatal neurons was of functional significance, as at 30 days, LPS-treated rats exhibited ipsiversive circling in response to (+)-amphetamine administration. At 24 h, there was a moderate increase in glial fibrillary acidic protein (GFAP)-ir astrocytes in the SN but a marked elevation of p47phox positive OX-42-ir microglia, and intense inducible nitric oxide synthase (iNOS)-ir and 3-nitrotyrosine (3-NT)-ir was present. However, by 30 days the morphology of OX-42-ir microglia returned to a resting state, the numbers were greatly reduced and no 3-NT-ir was present. At 30 days, GFAP-ir astrocytes were markedly increased in number and iNOS-ir was present in fibrillar astrocyte-like cells. This study shows that acute glial activation leading to dopaminergic neuron degeneration is an acute short-lasting response that does not itself perpetuate cell death or lead to prolonged microglial activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16045485     DOI: 10.1111/j.1460-9568.2005.04220.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  41 in total

1.  Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.

Authors:  N Rampersaud; A Harkavyi; G Giordano; R Lever; J Whitton; Ps Whitton
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

2.  Curcumin protects dopaminergic neurons against inflammation-mediated damage and improves motor dysfunction induced by single intranigral lipopolysaccharide injection.

Authors:  Neha Sharma; Sheetal Sharma; Bimla Nehru
Journal:  Inflammopharmacology       Date:  2017-04-13       Impact factor: 4.473

Review 3.  Oxidative and inflammatory pathways in Parkinson's disease.

Authors:  Rebecca L Miller; Marilyn James-Kracke; Grace Y Sun; Albert Y Sun
Journal:  Neurochem Res       Date:  2008-03-25       Impact factor: 3.996

Review 4.  Potential of animal models for advancing the understanding and treatment of pain in Parkinson's disease.

Authors:  Yazead Buhidma; Katarina Rukavina; Kallol Ray Chaudhuri; Susan Duty
Journal:  NPJ Parkinsons Dis       Date:  2020-01-06

Review 5.  Is Gut Dysbiosis an Epicenter of Parkinson's Disease?

Authors:  Charul Rajput; Alika Sarkar; Nidhi Sachan; Neeraj Rawat; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2021-01-05       Impact factor: 3.996

6.  Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss.

Authors:  Mahmoud M Iravani; Mona Sadeghian; Sarah Rose; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2014-04-30       Impact factor: 3.575

7.  Acute neuroimmune modulation attenuates the development of anxiety-like freezing behavior in an animal model of traumatic brain injury.

Authors:  Krista M Rodgers; Florencia M Bercum; Danielle L McCallum; Jerry W Rudy; Lauren C Frey; Kirk W Johnson; Linda R Watkins; Daniel S Barth
Journal:  J Neurotrauma       Date:  2012-04-26       Impact factor: 5.269

8.  Reversal of established traumatic brain injury-induced, anxiety-like behavior in rats after delayed, post-injury neuroimmune suppression.

Authors:  Krista M Rodgers; Yuetiva K Deming; Florencia M Bercum; Serhiy Y Chumachenko; Julie L Wieseler; Kirk W Johnson; Linda R Watkins; Daniel S Barth
Journal:  J Neurotrauma       Date:  2013-11-20       Impact factor: 5.269

Review 9.  Animal models of Parkinson's disease progression.

Authors:  Gloria E Meredith; Patricia K Sonsalla; Marie-Francoise Chesselet
Journal:  Acta Neuropathol       Date:  2008-02-14       Impact factor: 17.088

Review 10.  Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration.

Authors:  Maria E Figueiredo-Pereira; Chuhyon Corwin; John Babich
Journal:  Ann N Y Acad Sci       Date:  2016-01-08       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.